The size of the Asia-Pacific RNAi Drug Delivery Market has been estimated at USD 7.49 billion in 2020. It is projected to reach USD 26.76 billion by 2025, at a CAGR of 29% during the forecast period. RNA interference is a process in which RNA inhibits gene expression by degrading mRNA molecules. Gene silencing and sending artificial drugs to carry out these functions are also called Gene silencing, and that process is called RNAi Drug Delivery.
This method's growth is started in the last 15 years; before that, this method was applied only to the plants. Researchers are doing various types of experiments to minimize the side effects of drugs and invent new types of drugs.
Few factors like the Increasing incidence of chronic diseases like cancer and cardiovascular diseases and innovative Applications of the drug delivery market drive this market. Besides, Research carried out in the RNA Therapeutic field has also fueled the growth in Asia Pacific RNA Drug Delivery Market. But, High investments and stringent Regulations are some of the major restraints to this market. Targeted Delivery of RNAi Drugs is the key challenge faced by the market. Increasing investments by key players in this market are driving this market’s growth.
Asia-Pacific RNAi Drug Delivery market is segmented based on Drug Delivery and Therapeutic Application. Based on Drug Delivery, this market is further segmented into pulmonary drug delivery technology, aptamer drug delivery technology, nucleic acid drug delivery technology, and nanoparticle drug delivery technology. Based on Therapeutic Application, the market is further segmented into cardiology, metabolic disorders, oncology, ophthalmology, infectious diseases, and neurology.
Based on Geography, this market is further segmented into India, China, Japan, Australia, and South Korea. This region has the highest CAGR because of increased investments by key players in this region.
Key players in this region are Alnylam Pharmaceuticals Inc., Merck & Co. Inc, Dicerna Pharmaceuticals Inc., Tekmira Pharmaceuticals Corp., Access Pharmaceuticals Inc., Sirnaomics Inc., Isis Pharmaceuticals Inc, RXi Pharmaceuticals Corp., Calondo Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Silence Therapeutics plc, Traversa Therapeutics Inc., Marina Biotech Inc., Tacere Therapeutics Inc., and PhaseRx Inc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug delivery
5.1.2 nanoparticle drug delivery technology
5.1.3 pulmonary drug delivery technology
5.1.4 nucleic acid drug delivery technology
5.1.5 aptamer drug delivery technology
5.1.6 Y-o-Y Growth Analysis, By Drug Delivery
5.1.7 Market Attractiveness Analysis, By Drug delivery
5.1.8 Market Share Analysis, By drug Delivery
5.2 Therapeutic Application
5.2.2 infectious diseases
5.2.7 metabolic disorders
5.2.8 Y-o-Y Growth Analysis, By Therapeutic Application
5.2.9 Market Attractiveness Analysis, By Therapeutic Application
5.2.10 Market Share Analysis, By Therapeutic Application
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Drug Delivery
22.214.171.124 By Therapeutic Application
6.1.4 Market Attractiveness Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Drug Delivery
184.108.40.206 By Therapeutic Application
6.1.5 Market Share Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Drug Delivery
22.214.171.124 By Therapeutic Application
6.5 South Korea
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Alnylam Pharmaceuticals Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Merck & Co. Inc
8.3 Access Pharmaceuticals Inc.
8.4 Dicerna Pharmaceuticals Inc.
8.5 Tekmira Pharmaceuticals Corp.
8.6 Isis Pharmaceuticals Inc
8.7 Calondo Pharmaceuticals Inc.
8.8 Marina Biotech Inc.
8.9 RXi Pharmaceuticals Corp
8.10 Quark Pharmaceuticals Inc
8.11 Silence Therapeutics plc
8.12 Traversa Therapeutics Inc.
8.13 Tacere Therapeutics Inc
8.14 Sirnaomics Inc.
8.15 PhaseRx Inc.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures